Sarepta Therapeutics, Inc.
SRPT
$20.22
$0.160.80%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -17.96% | 13.13% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -17.96% | 13.13% | |||
| Cost of Revenue | -60.82% | 174.19% | |||
| Gross Profit | 252.95% | -150.94% | |||
| SG&A Expenses | 3.19% | -18.46% | |||
| Depreciation & Amortization | 10.98% | 0.00% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -52.59% | 110.42% | |||
| Operating Income | 138.48% | -285.79% | |||
| Income Before Tax | 140.06% | -323.31% | |||
| Income Tax Expenses | -167.59% | 404.10% | |||
| Earnings from Continuing Operations | 144.00% | -381.36% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 144.00% | -381.36% | |||
| EBIT | 138.48% | -285.79% | |||
| EBITDA | 143.53% | -268.71% | |||
| EPS Basic | 143.71% | -378.24% | |||
| Normalized Basic EPS | 138.73% | -277.68% | |||
| EPS Diluted | 141.02% | -385.34% | |||
| Normalized Diluted EPS | 135.60% | -300.18% | |||
| Average Basic Shares Outstanding | 0.66% | 1.12% | |||
| Average Diluted Shares Outstanding | 9.51% | -10.24% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||